Kanuma

Drug List

Kanuma

Drug Name

Kanuma (Sebelipase Alfa)

Manufactured By

Alexion Pharmaceuticals, Inc.

Drug Savings

Nationwide Prescription Connection (NPC) is an experienced advocacy service that helps connect patients to manufacturer provided free and discount programs. We can help the uninsured, under insured, those in the Medicare gap also known as the "doughnut hole", or even those needing help with expensive co-pays.  Our web site makes it easy for you to enter the medications you are taking, along with some basic patient information, and then finds the program that is right for you.

NPC's mission is your health. We recognize your need for help when you are applying for discount programs for your prescription medications. We consist of friendly and experienced advocates that not only know how these free and discount programs work, but are ready to help. We are available to take your call and answer any questions you may have as you search for the right program to fit your needs. We can also explain any supporting material you may need to provide as you apply for these programs. If for any reason you are denied, we also are experienced in the best appeals process with a high success rate.

Treats Disease/Condition

Uses

Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.

How To Use

Vials are for single-use only; discard any unused product. Use immediately after dilution; if immediate use is not possible, store ≤24 hrs at 2-8°C (36-46°F). Do not freeze or shake. Protect from light. Preparation 1. Determine the number of vials needed based on the patient's weight and the recommended dose of 1mg/kg or 3mg/kg. 2. Round to the next whole vial and remove required number of vials from refrigerator and allow to reach room temperature. 3. Mix gently by inversion; do not shake vials or prepared infusion Administration Administer sol as an IV infusion using a low-protein binding infusion set w/ an in-line, low-protein binding 0.2 micron filter. Infuse over ≥2 hrs; consider further prolonging the infusion time for patients receiving 3mg/kg dose or those who have experienced hypersensitivity reactions. A 1-hr infusion may be considered for patients receiving 1mg/kg dose who tolerate the infusion.

Side Effects

The most common side effects observed in patients treated with Kanuma are diarrhea, vomiting, fever, rhinitis, anemia, cough, headache, constipation, and nausea.

Drug Interactions

No information provided.

In Case of Overdose

There are no data on the presence of sebelipase alfa in human milk, the effects on the breastfed infant, or the effects on milk production. It is not known if sebelipase alfa is present in animal milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for KANUMA and any potential adverse effects on the breastfed infant from sebelipase alfa or from the underlying maternal condition.

In Case of Missed Dose

There are no data on the presence of sebelipase alfa in human milk, the effects on the breastfed infant, or the effects on milk production. It is not known if sebelipase alfa is present in animal milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for KANUMA and any potential adverse effects on the breastfed infant from sebelipase alfa or from the underlying maternal condition.

Storage